Serum Biomarkers of Clinical and Cytologic Response in Dogs with Idiopathic Immune‐Mediated Polyarthropathy. (3rd April 2014)

• Record Type: Journal Article
• Authors: Foster, J.D.; Sample, S.; Kohler, R.; Watson, K.; Muir, P.; Trepanier, L.A.
• Is Part Of: Journal of veterinary internal medicine. Volume 28:Number 3(2014:May/Jun.)
• Page Start: 905
• Page End: 911
• Publication Date: 2014-04-03
• Subjects: Veterinary medicine -- Periodicals; 636.0896
• DOI: 10.1111/jvim.12351
• Languages: English
• ISSNs: 0891-6640

Abstract

<abstract abstract-type="main" id="jvim12351-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jvim12351-sec-0001" sec-type="section"> <title>Background</title> <p>Immune‐mediated polyarthopathy (IMPA) is common in dogs, and is monitored by serial arthrocenteses.</p> </sec> <sec id="jvim12351-sec-0002" sec-type="section"> <title>Hypothesis/Objectives</title> <p>Plasma C‐reactive protein (CRP), interleukin‐6 (IL‐6), and CXCL8 (interleukin‐8) would serve as noninvasive markers of joint inflammation in IMPA.</p> </sec> <sec id="jvim12351-sec-0003" sec-type="section"> <title>Animals</title> <p>Nine client‐owned dogs with idiopathic IMPA; 6 healthy controls.</p> </sec> <sec id="jvim12351-sec-0004" sec-type="section"> <title>Methods</title> <p>Prospective study. Plasma CRP, IL‐6, and CXCL8 were measured by ELISA at baseline, 2, and 4 weeks during treatment with prednisone at 50 mg/m<sup>2</sup>/day. Arthrocenteses, the canine brief pain inventory (CBPI), and accelerometry collars were used to assess joint inflammation, lameness, and mobility at all 3 time points.</p> </sec> <sec id="jvim12351-sec-0005" sec-type="section"> <title>Results</title> <p>C‐reactive protein concentrations were higher in IMPA dogs (median 91.1 μg/mL, range 76.7–195.0) compared with controls (median <6.3 μg/mL, <6.3–13.7; <italic>P</italic> = .0035), and were significantly lower at week 2 (10.6 μg/mL, <6.3–48.8) and week 4 (<6.3 μg/mL, <6.3–24.4; <italic>P</italic> < .001).</p> <p>C‐reactive protein was correlated with median CBPI scores (<italic>r</italic> = 0.68; <italic>P</italic> = .0004), joint cellularity (<italic>r</italic> = 0.49, <italic>P</italic> = .011), and mobility by accelerometry (<italic>r</italic> = −0.42, <italic>P</italic> = .048). Plasma IL‐6 concentrations were also higher in IMPA dogs (median 45.9 pg/mL), compared with controls (median <15.7 pg/mL; <italic>P</italic> = .0008). IL‐6 was lower in IMPA dogs by week 4 (<15.7 pg/mL; <italic>P</italic> = .0099), and was modestly correlated with CBPI scores (<italic>r</italic> = 0.47, <italic>P</italic> = .023). CXCL8 did not differ significantly between IMPA and healthy dogs.</p> </sec> <sec id="jvim12351-sec-0006" sec-type="section"> <title>Conclusions</title> <p>Plasma CRP and IL‐6 might be useful surrogate markers of synovial inflammation and disease activity in dogs with IMPA.</p> </sec> </abstract>